Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Serum Uric Acid Level in Patients With Relapsing-Remitting Multiple Sclerosis Publisher Pubmed



Ashtari F1 ; Bahar M2 ; Aghaei M3 ; Zahed A4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Isfahan University of Medical Sciences, Isfahan Neuroscience Research Center, Isfahan, Iran
  2. 2. Immunology Research Center, Tehran University of Medical Sciences and Health Services, Tehran, Iran
  3. 3. Science and Research Branch, Islamic Azad University, Tehran, Iran
  4. 4. Department of Research and Technology, Isfahan University of Medical Sciences, Isfahan Neuroscience Research Center, Isfahan, Iran

Source: Journal of Clinical Neuroscience Published:2013


Abstract

Uric acid (UA) is a hydrophilic antioxidant product associated with multiple sclerosis (MS). We conducted a randomized case-control study to evaluate the serum level of UA in different phases of MS in comparison with levels in a healthy control population. Serum UA was checked in 130 patients with relapsing-remitting MS (85 patients in remitting and 45 patients in relapsing phase) and 50 age-matched controls using a quantitative enzyme-linked immunosorbent assay (ELISA). The mean concentrations of UA in serum was 6.41(±3.18) mg/dL in patients with remitting MS, 4.76(±1.66) mg/dL in patients with relapsing MS and 6.33(±2.94) mg/dL in controls. There was a significant difference between mean UA concentration in relapsing MS and remitting MS (p < 0.001), and between patients with relapsing MS and controls (p = 0.002); however, the difference between levels for patients in the remitting phase of MS and the control group was not significant (p = 0.87). It seems probable that UA has a role in the prevention of disease activity in MS. © 2012 Elsevier Ltd. All rights reserved.
Related Docs
View other Related Docs
1. Chlamydia Pneumoniae Seropositivity in Iranian Patients With Multiple Sclerosis: A Pilot Study; [Obecnosc Przeciwcial Przeciw Chlamydia Pneumoniae Wsrod Iranskich Chorych Na Stwardnienie Rozsiane: Badanie Pilotazowe], Neurologia i Neurochirurgia Polska (2011)
2. Serum Homocysteine Level in Patients With Multiple Sclerosis, Journal of Research in Medical Sciences (2005)
3. Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial, NeuroImmunoModulation (2014)
4. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
5. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
6. Cerebrospinal Fluid and Serum Markers of Inflammation in Patients With Multiple Sclerosis, Advances in Neuroimmune Biology (2017)
7. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
8. Short-Term Effects of Prolonged Fasting on Multiple Sclerosis, European Neurology (2009)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (105)
Vahid Shaygannejad (104)
Other Related Docs
9. Incidence and Prevalence of Multiple Sclerosis in Persian Gulf Area: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2020)
10. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
11. Color Blindness Among Multiple Sclerosis Patients in Isfahan, Journal of Research in Medical Sciences (2012)
12. Evaluation of Plasma Soluble Cd137 Level in Relapsing-Remitting Multiple Sclerosis Patients in Comparison With Healthy Controls in Isfahan Province, Iran, Neurology Asia (2020)
13. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
14. Effects of Low Dose Methotrexate on Relapsing-Remitting Multiple Sclerosis in Comparison to Interferon Β-1Α: A Randomized Controlled Trial, Journal of Research in Medical Sciences (2011)
15. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
16. Vitamin D Supplementation Could Limit T Helper-17 Response in Multiple Sclerosis, Clinical and Experimental Neuroimmunology (2014)
17. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
18. Evaluation of S100a12 and Apo-A1 Plasma Level Potency in Untreated New Relapsing–Remitting Multiple Sclerosis Patients and Their Family Members, Scientific Reports (2022)
19. Evaluation of Matrix Metalloproteinase-9 Plasma Levels in Untreated New Relapsing–Remitting Multiple Sclerosis Patients and Their First-Degree Family, Metabolic Brain Disease (2021)
20. Short-Term Effect of High-Dose Vitamin D on the Level of Interleukin 10 in Patients With Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, NeuroImmunoModulation (2015)
21. Serum Level of Interleukin 36 in Patients With Multiple Sclerosis, Journal of Immunoassay and Immunochemistry (2018)
22. Toll Like Receptor 2 and 4 Expression in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients, Iranian Journal of Immunology (2014)
23. The Efficacy and Safety of Ginger Supplementation in Patients With Multiple Sclerosis: A Rationale and Study Protocol for a Double-Blind Randomized Controlled Trial, Health Science Reports (2023)
24. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
25. Research Paper: The Association Between Salt and Potassium Intake With Multiple Sclerosis, Caspian Journal of Neurological Sciences (2019)
26. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
27. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
28. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
29. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
30. Co-Supplementation of Synbiotics and Anti-Inflammatory-Antioxidant Rich Diet in Patients With Progressive Forms of Multiple Sclerosis: A Single-Center, Randomized Clinical Trial, Mediterranean Journal of Nutrition and Metabolism (2024)
31. Serum Mercury Level and Multiple Sclerosis, Biological Trace Element Research (2012)
32. Decreased Serum Levels of Interleukin-35 Among Multiple Sclerosis Patients May Be Related to Disease Progression, Journal of Biological Regulators and Homeostatic Agents (2018)
33. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
34. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis, JAMA Neurology (2018)
35. Thalamic Asymmetry in Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
36. Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges, CNS and Neurological Disorders - Drug Targets (2018)
37. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
38. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
39. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
40. Seizure in Iranian Patients With Multiple Sclerosis, Journal of Research in Medical Sciences (2013)
41. Comparison of the Effect of Aspirin and Amantadine for the Treatment of Fatigue in Multiple Sclerosis: A Randomized, Blinded, Crossover Study, Neurological Research (2012)
42. Evaluation of the Frequency of Osteopontin Gene Polymorphism (Rs28357094 T>G) and Its Receptor Gene (Itga4- Rs1449263 A>G) in Multiple Sclerosis Patients in Comparison to Healthy Controls in Isfahan, Iran, Population, Journal of Isfahan Medical School (2016)
43. 25-Hydroxyvitamin D Concentrations in Patients With Optic Neuritis As a Clinically Isolated Syndrome and Healthy Controls, International Journal of Preventive Medicine (2012)
44. Comparison of the Efficacy and Side Effects of Ifn Beta 1-A (Rebif) and a Biosimilar Product (Recigen) in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2012)
45. The Frequency of Cognitive Dysfunction Among Multiple Sclerosis Patients With Mild Physical Disability, Journal of Isfahan Medical School (2012)
46. Research Paper: Comparison of Bladder Dysfunction and Urinary Symptoms Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, Caspian Journal of Neurological Sciences (2019)
47. The Prevalence of Restless Legs Syndrome (Rls) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis—An Update, Neurological Sciences (2023)
48. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
49. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
50. Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis, Current Medicinal Chemistry (2020)